| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.5 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.041 | 0.5 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.5 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.5 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | -0.043 | 0.5 |